Jakafi Xr
Jakafi Xr ingredients
| Active ingredient | Strength |
|---|---|
| Ruxolitinib | 55 mg/1, 33 mg/1, 11 mg/1, 44 mg/1, 22 mg/1 |
What Jakafi Xr is used for
The FDA lists the approved uses on the official label (below). In the EU, ruxolitinib is approved as Jakavi for:
Myelofibrosis (MF)Jakavi is indicated for the treatment of disease related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis.Polycythaemia vera (PV)Jakavi is indicated for the treatment of adult patients with polycythaemia vera who are resistant to or intolerant of hydroxyurea.Graft versus host disease (GvHD)Acute GvHDJakavi is indicated for the treatment of adults and paediatric patients aged 28 days and older with acute graft versus host disease who have inadequate response to corticosteroids or other systemic therapies (see section 5.1).Chronic GvHDJakavi is indicated for the treatment of adults and paediatric patients aged 6 months and older with chronic graft versus host disease who have inadequate response to corticosteroids or…
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Jakafi Xr
- Generic name
- Ruxolitinib
- Made by
- Incyte Corporation
- Forms
- Tablet, Extended Release
- Given
- Oral
- Drug class
- Janus Kinase Inhibitor, Kinase Inhibitor
- FDA approval
- New drug application (NDA) NDA217180
- On the US market since
- 2026
Official information
- Jakafi Xr prescribing information (FDA label) on DailyMed
- MedlinePlus drug information (search for Ruxolitinib)
In India
- Ruxolitinib: 3 brands in India
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Jakafi Xr?
Jakafi Xr (Ruxolitinib) is a cancer medicine made by Incyte Corporation, approved by the US FDA.
What are the ingredients of Jakafi Xr?
Jakafi Xr contains Ruxolitinib (55 mg/1, 33 mg/1, 11 mg/1, 44 mg/1, 22 mg/1).
Is Jakafi Xr approved in Europe?
The same active substance is approved in the EU as Jakavi.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA